8-K: MannKind Completes scPharmaceuticals Acquisition
Sentiment:
Merger Completion
MannKind Corporation has completed its acquisition of scPharmaceuticals Inc. for $5.35 per share in cash plus a contingent value right, making scPharmaceuticals a wholly-owned subsidiary.
Summary
- The acquisition of scPharmaceuticals Inc. by MannKind Corporation was completed on October 7, 2025, through a merger where MannKind's subsidiary, Seacoast Merger Sub, Inc., merged into scPharmaceuticals.
- The Offer Price for each share of scPharmaceuticals common stock was $5.35 in cash, plus one non-tradable Contingent Value Right (CVR) per share, which represents the right to receive up to an aggregate of $1.00 per CVR in cash upon achievement of certain regulatory and net sales milestones.
- The tender offer expired on October 6, 2025, with 39,933,692 shares (approximately 73.47% of outstanding shares) validly tendered and not withdrawn.
- An additional 5,930,025 shares (approximately 10.91% of outstanding shares) were subject to guaranteed delivery procedures.
- All conditions to the tender offer were satisfied, leading to the prompt acceptance and payment for tendered shares.
- scPharmaceuticals' common stock was delisted from The Nasdaq Global Select Market, and trading was halted prior to the open of trading on October 7, 2025.
- The company terminated its Credit Agreement and Guaranty, Revenue Participation Right Purchase and Sale Agreement, and the 2017 Employee Stock Purchase Plan (ESPP) in connection with the merger.
- Outstanding Company Options and Restricted Stock Unit (RSU) Awards were converted into cash and CVRs, with payments to current or former employees expected within 15 days of the Effective Time.
- All Company Warrants were exercised prior to the Effective Time, and the underlying shares were treated in the same manner as other outstanding shares.
Sentiment
Score: 7
Explanation: The completion of the merger provides a clear exit for shareholders at a defined cash price with potential upside from CVRs. The process appears to have concluded smoothly and as expected, resolving uncertainty for investors. However, the CVRs introduce future contingency.
Positives
- The acquisition provides immediate liquidity to scPharmaceuticals shareholders at $5.35 per share in cash.
- Shareholders also receive potential future upside through Contingent Value Rights (CVRs) of up to $1.00 per CVR, tied to specific regulatory and net sales milestones.
- Existing credit agreements and revenue participation rights were fully repaid and terminated, resolving previous financial obligations.
Negatives
- scPharmaceuticals Inc. ceases to be an independent publicly traded company, ending its separate corporate existence.
- The company's common stock has been delisted from Nasdaq, eliminating public trading opportunities for investors.
- The 2017 Employee Stock Purchase Plan (ESPP) was terminated, discontinuing this benefit for employees.
- Shareholders lose direct ownership, voting rights, and the ability to trade scPharmaceuticals stock on a public exchange.
Risks
- The full value of the Contingent Value Rights (CVRs), up to $1.00 per CVR, is not guaranteed and is dependent on the achievement of future regulatory and net sales milestones.
- Former shareholders no longer have exposure to the company's future growth or performance beyond the CVR terms, as it is now a wholly-owned subsidiary.
Future Outlook
The company, now a wholly-owned subsidiary of MannKind Corporation, will no longer be publicly traded. Future operations and strategic direction will be determined by MannKind, with potential contingent payments to former shareholders based on regulatory and net sales milestones.
Management Comments
- The resignations of the former directors from the Board were not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Industry Context
This acquisition reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger companies acquire smaller, specialized firms to expand product pipelines or market share. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future risks/rewards, particularly for assets with significant regulatory or commercial hurdles remaining.
Comparison to Industry Standards
- The use of a tender offer followed by a short-form merger (Section 251(h) of the DGCL) is a standard and efficient method for acquisitions of public companies, especially when a significant majority of shares are tendered.
- The inclusion of CVRs in the deal structure is a common practice in pharmaceutical and biotech acquisitions, allowing the acquirer to mitigate risk associated with future product performance or regulatory approvals, while providing target shareholders with potential upside. This structure is seen in deals like the acquisition of Acceleron Pharma by Merck or the acquisition of The Medicines Company by Novartis.
- The delisting from Nasdaq and termination of SEC reporting obligations are standard procedures following a successful acquisition and privatization of a public company.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | John H. Tucker | NA | 2025-10-07 | Resigned in connection with merger completion. |
| Director | William T. Abraham, MD | NA | 2025-10-07 | Resigned in connection with merger completion. |
| Director | Mette Kirstine Agger | NA | 2025-10-07 | Resigned in connection with merger completion. |
| Director | Minnie V. Baylor-Henry | NA | 2025-10-07 | Resigned in connection with merger completion. |
| Director | Sara Bonstein | NA | 2025-10-07 | Resigned in connection with merger completion. |
| Director | Frederick Hudson | NA | 2025-10-07 | Resigned in connection with merger completion. |
| Director | Jack A. Khattar | NA | 2025-10-07 | Resigned in connection with merger completion. |
| Director | Leonard D. Schaeffer | NA | 2025-10-07 | Resigned in connection with merger completion. |
| Director | Klaus Veitinger, MD, PhD | NA | 2025-10-07 | Resigned in connection with merger completion. |
| Director | NA | Michael E. Castagna | 2025-10-07 | Appointed in connection with merger completion. |
| Director | NA | David Thomson | 2025-10-07 | Appointed in connection with merger completion. |
| Director | NA | Chris Prentiss | 2025-10-07 | Appointed in connection with merger completion. |
| President and Chief Executive Officer | Previous executive officer | Michael E. Castagna | 2025-10-07 | Appointed in connection with merger completion. |
| Chief Financial Officer | Previous executive officer | Chris Prentiss | 2025-10-07 | Appointed in connection with merger completion. |
| Secretary | Previous executive officer | David Thomson | 2025-10-07 | Appointed in connection with merger completion. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Certificate of Incorporation Amendment | The company's second amended and restated certificate of incorporation was amended and restated in its entirety, becoming the Third Amended and Restated Certificate of Incorporation of scPharmaceuticals Inc. Key changes include setting the total authorized shares to 1,000 shares of common stock with a par value of $0.0001 per share, and provisions for director liability and indemnification. | 2025-10-07 | Reflects the company's new status as a wholly-owned subsidiary, significantly reducing the number of authorized shares as it is no longer publicly traded. Standardizes director liability and indemnification provisions post-merger. |
| Bylaws Amendment | The company's amended and restated bylaws were amended and restated in their entirety, becoming the Second Amended and Restated Bylaws of scPharmaceuticals Inc. Changes include provisions for stockholder meetings (annual and special), quorum, voting, proxies, record dates, and actions by written consent, all tailored for a private, wholly-owned subsidiary. Also details board of directors structure, committees, officer roles, stock certificates, notices, and extensive indemnification provisions. | 2025-10-07 | Aligns corporate governance with its new status as a wholly-owned subsidiary, streamlining internal operations and removing requirements pertinent to a publicly traded entity. The detailed indemnification provisions are standard for protecting directors and officers. |
| Plan Termination | The 2017 Employee Stock Purchase Plan (ESPP) was terminated. | 2025-10-07 | Ends employee stock purchase benefits, consistent with the company no longer being publicly traded. |
Stakeholder Impact
- Shareholders: Received $5.35 cash per share plus one CVR, providing immediate liquidity and potential future upside. Lost direct ownership and voting rights as the company is now private.
- Employees: The Employee Stock Purchase Plan (ESPP) was terminated. Executive officers were replaced by new appointments from MannKind Corporation.
- Creditors: Existing Credit Agreement and Revenue Participation Right Purchase and Sale Agreement were fully repaid and terminated, resolving previous debt obligations.
- Management: Former directors and executive officers resigned; a new management team was appointed by MannKind Corporation to oversee the surviving entity.
Next Steps
- Payment of the Offer Price for all validly tendered and not withdrawn shares will be made promptly.
- Payments for converted Company Options and RSU Awards will be made as soon as reasonably practicable, but no later than fifteen (15) days after the Effective Time.
- Nasdaq is expected to file Form 25 with the SEC on October 7, 2025, to effect the delisting and deregistration of shares.
- The company intends to file Form 15 with the SEC to terminate registration of shares under the Exchange Act and suspend its reporting obligations as promptly as practicable.
Key Dates
| Date | Description |
|---|---|
| 2017-10-23 | Original filing date of Registration Statement on Form S-1 for the 2017 Employee Stock Purchase Plan (ESPP). |
| 2017-11-16 | Effective date of Registration Statement on Form S-1 for the ESPP. |
| 2024-08-09 | Date of the Credit Agreement and Guaranty and the Revenue Participation Right Purchase and Sale Agreement. |
| 2025-08-24 | Date of the Agreement and Plan of Merger. |
| 2025-08-25 | Date of previous 8-K filing disclosing the Merger Agreement. |
| 2025-09-08 | MannKind Corporation, through Purchaser, commenced a tender offer to purchase outstanding shares. |
| 2025-10-06 | Expiration Date of the tender offer (one minute after 11:59 p.m., Eastern time). |
| 2025-10-07 | Closing Date of the acquisition and merger; trading halted; directors resigned; new directors and officers appointed; certificate of incorporation and bylaws amended. |
Keywords
scPharmaceuticals, MannKind Corporation, Merger, Acquisition, Tender Offer, Delisting, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals, Corporate Governance, SEC Filing, 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.